UTHR Relative Valuation
UTHR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, UTHR is overvalued; if below, it's undervalued.
Historical Valuation
United Therapeutics Corp (UTHR) is now in the Undervalued zone, suggesting that its current forward PE ratio of 10.69 is considered Undervalued compared with the five-year average of 11.98. The fair price of United Therapeutics Corp (UTHR) is between 402.69 to 483.66 according to relative valuation methord. Compared to the current price of 297.33 USD , United Therapeutics Corp is Undervalued By 26.16%.
Relative Value
Fair Zone
402.69-483.66
Current Price：297.33
26.16%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.97
P/B
Median3y
2.24
Median5y
2.21
8.53
FCF Yield
Median3y
6.52
Median5y
7.11
Competitors Valuation Multiple
The average P/S ratio for UTHR's competitors is 7.09, providing a benchmark for relative valuation. United Therapeutics Corp Corp (UTHR) exhibits a P/S ratio of 4.05, which is -42.82% above the industry average. Given its robust revenue growth of 17.22%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is United Therapeutics Corp (UTHR) currently overvalued or undervalued?
What is United Therapeutics Corp (UTHR) fair value?
How does UTHR's valuation metrics compare to the industry average?
What is the current P/B ratio for United Therapeutics Corp (UTHR) as of Jul 18 2025?
What is the current FCF Yield for United Therapeutics Corp (UTHR) as of Jul 18 2025?
What is the current Forward P/E ratio for United Therapeutics Corp (UTHR) as of Jul 18 2025?